Journal of Medical Internet Research (Aug 2021)

Obesity and BMI Cut Points for Associated Comorbidities: Electronic Health Record Study

  • Natalie Liu,
  • Jen Birstler,
  • Manasa Venkatesh,
  • Lawrence Hanrahan,
  • Guanhua Chen,
  • Luke Funk

DOI
https://doi.org/10.2196/24017
Journal volume & issue
Vol. 23, no. 8
p. e24017

Abstract

Read online

BackgroundStudies have found associations between increasing BMIs and the development of various chronic health conditions. The BMI cut points, or thresholds beyond which comorbidity incidence can be accurately detected, are unknown. ObjectiveThe aim of this study is to identify whether BMI cut points exist for 11 obesity-related comorbidities. MethodsUS adults aged 18-75 years who had ≥3 health care visits at an academic medical center from 2008 to 2016 were identified from eHealth records. Pregnant patients, patients with cancer, and patients who had undergone bariatric surgery were excluded. Quantile regression, with BMI as the outcome, was used to evaluate the associations between BMI and disease incidence. A comorbidity was determined to have a cut point if the area under the receiver operating curve was >0.6. The cut point was defined as the BMI value that maximized the Youden index. ResultsWe included 243,332 patients in the study cohort. The mean age and BMI were 46.8 (SD 15.3) years and 29.1 kg/m2, respectively. We found statistically significant associations between increasing BMIs and the incidence of all comorbidities except anxiety and cerebrovascular disease. Cut points were identified for hyperlipidemia (27.1 kg/m2), coronary artery disease (27.7 kg/m2), hypertension (28.4 kg/m2), osteoarthritis (28.7 kg/m2), obstructive sleep apnea (30.1 kg/m2), and type 2 diabetes (30.9 kg/m2). ConclusionsThe BMI cut points that accurately predicted the risks of developing 6 obesity-related comorbidities occurred when patients were overweight or barely met the criteria for class 1 obesity. Further studies using national, longitudinal data are needed to determine whether screening guidelines for appropriate comorbidities may need to be revised.